15.78 USD
▲+0.02+0.13%
盘后 17.94 0.00%
2026-11-19
市值
$2.25B
市盈率
—
EPS
-3.64
股息率
—
52 周区间
15.65 – 31.74
成交量
1.07M
Beta
1.09
目标价
40.92
52W 低 15.6552W 高 31.74
价格走势
公司简介
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in...